CSL Ltd Annual Report 2021

Donor management A division of CSL Behring, CSL Plasma collects the plasma that is the foundation to manufacturing plasma-protein therapies – human plasma donated across one of the largest global plasma collection networks. CSL Plasma has more than 300 collection centres around the world, primarily in the US as well as in Germany, Hungary and China. CSL Plasma operates plasma testing laboratories and logistics centres in the US, Germany and China. In addition, a US manufacturing facility produces saline and sodium citrate, both essential solutions to the plasma donation process. CSL Plasma continues to invest in new collection centre growth, as well as laboratory and logistics operations to automate and expand testing and storage capacities. We continue to strengthen and grow the CSL Plasma footprint to support a safe and reliable plasma supply to meet increasing patient demand. A quality supply of rawmaterial results from safe, compliant and efficient plasma collection and donor management. Over the reporting period, 461,715 surveys completed by CSL Plasma donors indicated 99% would be willing to donate again and 97% would be willing to refer a friend to donate.* CSL Plasma donor profile The socio-economic background of US CSL Plasma donors remains diverse. Based on self-reported survey data (1 July 2020 to 30 June 2021), CSL Plasma donors provided details on their occupational status*: – 48% described themselves as working full-time; – 27% described themselves as unemployed, inclusive of full-time parents, donors who are not looking for work or unemployed; – 13% described themselves as part-time; – 2% described themselves as students; and – 10% described themselves as other (e.g. military, retired). 99% of plasma donors are willing to donate again* 97% of plasma donors are willing to refer a friend to a centre* Innovation at CSL Plasma CSL Plasma upholds a tradition of innovation and customer focus. In April 2021, CSL Plasma and Terumo Blood and Cell Technologies together announced a collaboration to develop and deliver a new plasma collection platform at US CSL Plasma collection centres. A clinical trial of the investigational plasmapheresis device began in April. Introduction of the new plasmapheresis platform is subject to the US Food and Drug Administration device clearance. A subsidiary of Tokyo-based Terumo Corporation (TSE:4543), Terumo Blood and Cell Technologies is a medical technology company whose products, software and services enable customers to collect and prepare blood and cells for the treatment of challenging diseases and conditions. Our collaboration with Terumo Blood and Cell Technologies to develop plasmapheresis technology is consistent with our aims to improve the donor and operator experience, and remain the plasma donation centre of choice for the future. We continue to explore process improvements and technological advancements in plasma collection to drive efficiency while maintaining donor safety and a sufficient plasma supply. * Limited assurance by Ernst & Young. CSL Limited Annual Report 2020/21 37